OKYO
NASDAQOKYO Pharma Limited
News · 26 weeks56-82%
2025-10-262026-04-19
Mix3790d
- SEC Filings20(54%)
- Other8(22%)
- M&A3(8%)
- Offering2(5%)
- Insider2(5%)
- Leadership1(3%)
- Other1(3%)
Latest news
25 items- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual MeetingLONDON and NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it will hold a key Scientific Advisory Board (SAB) meeting with leading ophthalmology experts during the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, DC. The SAB meeting, scheduled to take place alongside the conference, will bring together prominent corneal and ocular surface disease specialists to review clinical data for the company's lead candidate, urcosimod and
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma Announces Chairman and Founder Acquires SharesLONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 10,119 of the Company's ordinary shares on NASDAQ at $1.59, bringing his total holding to 10,526,416 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma Announces Director Acquires SharesLONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that John Brancaccio, Non-Executive Director, has acquired 5,000 of the Company's ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma Announces Chief Development Officer and Director Acquires SharesLONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Gary Jacob, Chief Development Officer and Director, has acquired 30,980 of the Company's ordinary shares on NASDAQ at $1.59, bringing his total holding to 108,920 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammat
- INSIDERSEC Form 3 filed by new insider Jacob Gary S3 - OKYO Pharma Ltd (0001849296) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cerrone Gabriele M3 - OKYO Pharma Ltd (0001849296) (Issuer)
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal PainLONDON and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced new positive findings from an exploratory analysis of patient-reported outcomes in its recently completed Phase 2a trial of urcosimod (0.05%) for the treatment of NCP. This new quality-of-life (QoL) data will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting. The presentation, titled: "First-in-Human Study of Urcosimod to Treat Neuropathic Corneal Pain (NCP) Shows Clinic
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Abstract Selected for Presentation at Premier Global Ophthalmology CongressLONDON and NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that its abstract has been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting, taking place May 3-7, 2026, in Denver, Colorado. Chief Scientific Officer Raj Patil, Ph.D., will share the data in a presentation titled: "First-in-Human Study of Urcosimod to Treat Neuropathic Corneal Pain (NCP) Shows Clinically Meaningful Pain Reduction and Quality-of-Life Improve
- ANALYSTPiper Sandler initiated coverage on OKYO Pharma with a new price targetPiper Sandler initiated coverage of OKYO Pharma with a rating of Overweight and set a new price target of $7.00
- SECSEC Form SCHEDULE 13G filed by OKYO Pharma LimitedSCHEDULE 13G - OKYO Pharma Ltd (0001849296) (Subject)
- SECSEC Form 424B5 filed by OKYO Pharma Limited424B5 - OKYO Pharma Ltd (0001849296) (Filer)
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary SharesLONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced the pricing of an underwritten public offering (the "Offering") of 10,815,000 ordinary shares at an offering price of $1.85 per ordinary share. The Company has granted the underwriter a 30-day option to purchase up to an additional 1,622,250 ordinary shares at the public offering price, less underwriting discounts and commissions. The gross proceeds to the Company from the Offering, before deducting offering expenses pay
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- SECSEC Form 424B5 filed by OKYO Pharma Limited424B5 - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma Announces Public Offering of Ordinary SharesLONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it intends to offer to sell its ordinary shares in an underwritten public offering (the "Offering"). All of the ordinary shares are to be sold by the Company. The Company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of ordinary shares sold in this Offering at the public offering price, less underwriting discounts and commissions. The Offering is subject to market
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)